Neurotransmission Failure
Neurotransmission Failure - Related Videos
01:27
Adrenergic Neurons: Neurotransmission
0 Views •
2023
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism. Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
07:41
Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
0 Views •
Cited by 2 •
2017
Fast-scan cyclic voltammetry can monitor in vivo dopamine neurotransmission in the context of drugs, disease, and other experimental manipulations. This work describes the implementation of QNsim1.0, a software to model electrically stimulated dopamine responses according to the quantitative neurobiological model to quantify estimates of dopamine release and reuptake dynamics.
01:23
Cholinergic Neurons: Neurotransmission
0 Views •
2023
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
01:29
Visualizing Neurotransmission Using Fluorescent False Neurotransmitters
0 Views •
2025
Incubate the slice in aCSF containing fluorescent false neurotransmitters or FFNs.
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
0 Views •
Cited by 21 •
2011
A method of gene transfer for the treatment of ischemic heart failure is described using a swine model of myocardial infarction. Our simple and reproducible method enables us to readily evaluate the efficacy of various gene transfers with a very simple and reproducible way.
FAQs
A synthesis or storage problem limits the amount of neurotransmitter available before signaling begins, whereas a release defect prevents an adequately prepared signal from leaving the presynaptic neuron after an action potential. This distinction focuses investigation on different stages of transmission and helps identify whether treatment should support transmitter availability or modify release mechanisms.
Even when neurotransmitter release is preserved, signaling can fail if postsynaptic receptors do not recognize the transmitter or if altered ion gradients prevent the appropriate electrical response. These mechanisms separate delivery of a chemical message from conversion into neuronal activity, helping explain why intact release does not necessarily produce normal nervous-system function.
Reuptake and enzymatic degradation normally regulate how long neurotransmitters remain available after release. If either process changes, signaling may become insufficient because the transmitter is removed too quickly, or abnormal because it persists too long. Pharmacological analysis therefore treats clearance as a distinct control point rather than assuming every synaptic problem begins with release.
The failure points depend on the signaling mode. Chemical transmission can be examined through transmitter synthesis, storage, release, receptor recognition, reuptake, and enzymatic breakdown. Electrical transmission is additionally sensitive to ion gradients. This comparison helps pharmacologists avoid attributing every communication defect to neurotransmitter availability when altered electrical conditions may be involved.
A practical analysis traces signaling in sequence: transmitter preparation, action-potential-dependent release, postsynaptic recognition, and signal termination. Researchers then identify which stage is altered and consider whether a drug changes release, receptor activity, reuptake, or enzymatic breakdown. This workflow links a molecular failure point with its likely functional consequence and therapeutic target.
These strategies are relevant when the principal defect lies in how much transmitter reaches the synapse or how the postsynaptic cell responds to it. Modifying release or receptor activity can help restore signaling, but the same intervention may also produce adverse effects if communication becomes excessive or occurs in unintended neural circuits.
Mapping the disrupted stage can connect synaptic events with altered nervous-system function and guide medicine development. Studies may reveal whether a candidate treatment restores transmitter availability, improves receptor-mediated signaling, or normalizes signal termination. They can also clarify why a drug produces therapeutic effects alongside unwanted effects, supporting more precise pharmacological design.